Agilex has offered our clients small molecule solutions that lead to their success. Agilex Biolabs is celebrating its 29th year...
For 3 decades, Agilex has supported biotech companies with CNS-targeted medicines. For almost 3 decades, Agilex Biolabs has sup...
Let's face it – we are an aging population throughout the world. More and more, we are seeing these neurological disorders growi...
In molecular biology and pharmacology, small molecules are noted for their ability to quickly modulate their actions. This is beca...
Applying Decades of Experience with an Eye on the Future of Small Molecule Development For decades before antibody drugs were d...
Looking beyond the surface on the Complexity of Atopic Dermatitis Addressing inflammatory skin disorders like atopic dermatitis...
We took some time to sit down and talk with Jason so you could get to know him a bit better... My name is Jason Valentine. I'm...
We took some time to sit down and talk with Cameron so you could get to know him a bit better... My name is Cameron Smith. I'm...
We took some time to sit down and talk with Dr Sales so you could get to know him a bit better... My name is Kurt Sales. I’m...
Unraveling the Untapped Potential of Immuno-Oncology Technology Both the pace and varied methods by which medical clinicians ut...
A Quick Look at Agilex Biolabs' Expertise and Capabilities In the intricate landscape of drug discovery and development, the as...
Agilex Biolabs has extensive knowledge on small molecule development and pharmacokinetic services. Today, pharmacokinetics (PK)...
Agilex Biolabs integrates critical reagents services into comprehensive lifecycle management. The relationship between producin...
Agilex is pleased to introduce Mallory Jolly as our new Senior Business Development Director to the East Coast of the United State...
Agilex Demystifies the Rapidly Evolving Landscape of Drug Development Post-Covid, the field of bioanalysis has undergone signif...
As Agilex Biolabs continues its global expansion and corporate evolution as part of the Healius network, Stephen McIntyre has been selected to take the position of Chief Executive Officer.
ddPCR technology provides an opportunity to streamline research and development processes, saving time and money. Digital dropl...
Small and large molecule drug development often necessitates distinct analytical methodologies. Agilex has extensive experience de...
Agilex has extensive experience developing and validating like-binding assays for specific immune-oncology therapeutics. From a...
Come to Our EBF Session in Barcelona to Hear how Agilex Can Make Your PK Data SPARCL SPARCL stands for Spatial Proximity Analyt...
How do Australia's streamlined regulatory process and global tax incentive apply to your toxicology studies? There are many ben...
As Agilex Biolabs continues its global expansion and corporate evolution as part of the Healius network, Stephen McIntyre has been selected to take the position of Chief Executive Officer.
by Holly Stefl, Chief Commercial Officer It is with much enthusiasm that Agilex Biolabs introduces its newest Senior Developmen...
by Kurt Sales In the realm of bioanalytical research, immunoassays stand as a cornerstone technology, enabling the precise dete...
